identified 50 strains of Acinetobacter baumannii and 119 strains of Klebsiella spp. During that all the 50 strains of Acinetobacter baumannii were evaluated as resistant to penicillins and to 1st, 2nd and 3rd generation cephalosporins. The exception was found in the «protected» β-Lactam antibioticspiperacillin/tazobactam and cefoperazone/ sulperazone. The sensitivity to them was 100 %. Cefepime -a 4th generation cephalosporinproved of little efficiency stirring sensitivity in 10 % of Acinetobacter baumannii strains only. The sensitivity to carbapenems proved insufficient as well with 40 % of bacterial strains only evaluated as sensitive to imipenem and meropenem. Virtually inefficient in vitro were aminoglycosides (gentamycin and amikacin), ciprofloxacin, levomycetin and cotrimoxazole. Resistance to doxycycline was revealed in 48 % of Acinetobacter baumannii strains, while tigecycline's activity was at 100 %.
Therefore, in case of nosocomial infections caused by Acinetobacter baumannii an advisable choice would be either "protected" β-Lactam antibiotics (namely piperacillin/tazobactam or cefoperazone/sulperazone) or tigecycline. Carbapenems and 2 nd and 3 rd generation fluoroquinolones could be viewed as an option only after a preliminary bacteriologic study of the patient's material.
The isolated strains of Klebsiella spp. (84 % of them accounted for by Klebsiella pneumoniae) also proved resistant to penicillins and 1 st , 2 nd and 3 rd generation cephalosporins. Cefepime was effective in vitro in 21 % of cases alone; at the same time the microorganisms showed high sensitivity to piperacillin/tazobactam (100 %) and cefoperazone/ sulbactam (92.4 %). To carbapenems (imipenem and meropenem) only 60.5 % Klebsiellae were sensitive, while a low level of sensitivity (below 30 % of strains) was detected to aminoglycosides (gentamycin and amikacin), ciprofloxacin, levomycetin, and co-trimoxazole. Ofloxacin/levofloxacin caused resistance in 60 % of microorganisms, while doxycycline -in 52 %. Tigecycline showed a high level of efficiency with 100 % of Klebsiella spp. of strains sensitive to it. Mention to be made here that around 40 % of Klebsiellae strains produced extended spectrum beta lactamases (ESBL). This means that in hospital setting in case of infections caused by Klebsiella spp. a preferred choice would be either piperacillin/tazobactam or cefoperazone/sulperazone, or tigecycline. Employing carbapenems, ofloxacin/levofloxacin or doxycycline could allow us counting on a proper effect in slightly more than 50 % of cases.
Conclusion. Developing the resistance in hospital environment microorganisms would have a significant impact on the treatment outcomes regarding patients with nosocomial infections. A bacteriologic monitoring of such microorganisms evaluating their resistance to a wide range of anti-microbial medications should be a mandatory activity not only in particular inpatient units yet in the region as a whole. This work would contribute both to the development of general standard requirements for empirical therapy of infections in hospitals and to establishing individual approaches when shaping the therapeutic tactics for particular patients.
